April 17, 2019 11:27 AM EDTUpdated April 18, 01:06 PM
R&D

Glax­o­SmithK­line R&D re­or­ga­ni­za­tion trig­gers lay­offs at Steve­nage -- and Up­per Prov­i­dence

John Carroll

Editor & Founder

GSK’s new R&D chief Hal Bar­ron has made no se­cret of the fact that he has a keen in­ter­est in re­fo­cus­ing the R&D group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times